Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

What's Next in Pfizer's M&A Ramp-Up?

TheMotleyFool

0 0

Despite record-breaking earnings, a rock-bottom valuation, and a top-notch dividend yield, Pfizer's (NYSE: PFE) shares have slid by an unsightly 17.3% so far this year.

Pfizer's stock price has been under pressure this year for a variety of reasons, including but not limited to the following:

Over the past two years, the drugmaker has significantly ramped up its deal-making in an effort to add $25 billion of risk-adjusted revenue by 2030. Here are Pfizer's most significant deals over this period:

Source Fool.com

Like: 0

PFE

Share